From Immune System Damage to Podocyte Cell Damage: Prospective Database and Biological Collection of Patients (Children and Adults) With MGLS and HSFP

NCT04174066 · tracked via the Priya Life Science France tracker

Sponsor

Centre Hospitalier Universitaire de Nice

Phase

Observational

Started

2020-05-20

Last updated

2026-06-22

Condition(s) studied

Nephrotic Syndrome

Investigational drug(s) / intervention(s)

blood sampletissue sampleexcreta

blood sample: blood sample during planned in the follow-up of patients.

tissue sample: tissue sample during planned in the follow-up of patients.

excreta: urine sample during planned in the follow-up of patients.

Study summary

Idiopathic Nephrotic Syndrome (INS) is a kidney disease characterized by massive proteinuria and hypoalbuminemia. It includes two anatomopathological entities: nephrotic syndrome with minimal glomerular lesions (SNLGM) and primary segmental and focal hyalinosis (PHF). Renal biopsy reveals a fusion of the feet of the podocytes without inflammatory lesions or deposits of immune complexes. Clinical and experimental observations strongly suggest that the immune system and podocyte dysfunction are the two facets of the disease. There are currently no clinical or biological markers to predict the diagnosis of corticosteroid sensitivity, corticosteroid dependence, or risk of recurrence of kidney disease after kidney transplantation. To our knowledge, no prospective studies have been designed to study both immune system alterations and podocyte damage as well as genetic predisposition variants in NIS. Therefore, the use of steroids/immunosuppressive agents is purely empirical with a multitude of side effects.

The objective is to identify and test new therapeutic targets rather than conducting new trials with existing treatments, using either drug candidates or molecules selected by high throughput screening of libraries of repositioning molecules using an appropriate read-out. The biobank may also be used to analyze the effects of conventional treatments on identified new biomarkers. We expect the project to produce original and patentable results with subsequent valuation. Patentability will be anticipated before any publication on the subject. The patent and valorization cells of hospitals, INSERM and Universities will be involved in the results as soon as they are obtained.

Eligibility

Sex

ALL

Min age

12 Months

Max age

—

Healthy volunteers

Inclusion Criteria: * First episode of idiopathic nephrotic syndrome in a child aged 12 months to 18 years with a weight \> 10 kg and biologically defined as proteinuria \> 0.20 g / mmol creatinuria and hypoalbuminemia \<25 g / mmol * First episode of NIS defined in adults as albumin level \<30 g / L and a urinary protein/creatinine ratio (UPCR) ≥ 300 mg / mmol systematically associated with the performance of a renal anatomopathological examination and characterized by the absence of identifiable lesions by light microscopy (SNLGM) or the presence of HSF lesions. * For adults: signed informed consent to participate in the study * For children: patients will be informed and a written informed consent form will be signed by both parents of the children at inclusion * Patients affiliated to the French health system Exclusion Criteria: * Patients who have previously received corticosteroids and/or immunosuppressants * Patients with reduced CH50 and/or low C3 and/or low C4 and/or low C4 (in some cases increased sC5b9 and/or presence of a C3 nephritic Factor; an anti-C3b...) * SNLGM resulting from a secondary process (lymphoid hematopathies or neoplasia) or occurring following the administration of a treatment known to be associated with an SNLGM (lithium, interferon, non-steroidal anti-inflammatory drugs) * Non-primary FHH (absence of Nephrotic Syndrome, etiological assessment revealing FHH secondary to an identified cause (genetic or not), no introduction of corticosteroids or immunosuppressants as first-line treatment) * Positive serological screening test for HIV, hepatitis B or C * Positive immunological tests for antinuclear and anti-DNA antibodies or anti-PLA2R1 and anti-THSD7A * Patient under guardianship or curatorship

Primary outcome measure(s)

number of biological samples — 5 years
establish in each centre a prospective collection of blood, urine and kidney biopsy samples sampled and stored in accordance with standard operating procedures, supported by a harmonized clinical and biological database

Trial sites (2)

Facility	City	Region	Status
Nice Hospital	Nice	France	Recruiting
APHP	Paris	France	Recruiting

More Centre Hospitalier Universitaire de Nice trials in France

Methotrexate Treatment in Hand Osteoarthritis Refractory to Usual Treatments Recruiting

Immunopathological Analysis in a French National Cohort of Membranous Nephropathy Recruiting

Biological & Fonctional Signatures for Muscle Failures, Aged People & Personalized Physical Activity Recruiting

A Study of the Correlation Between the Severity of Substance Use Disorder and the Intensity of Dependence on Generative Artificial Intelligence Starting soon

Impact of an e-Bug Educational Intervention on HPV Vaccine Uptake in Middle School Students Recruiting

Other trials for the same condition

Single-cell RNA Sequencing (scRNA-seq) to Investigate the Mechanisms Underlying the Induction of Regulatory T Cells in Patients With Extramembranous Glomerulonephritis Treated With Rituximab Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04174066 on ClinicalTrials.gov ↗ ← All trials in France